Suppr超能文献

人CD34(+)脐血细胞体外扩增后植入非肥胖糖尿病严重联合免疫缺陷小鼠:再植干细胞扩增和自我更新的证据

Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells.

作者信息

Piacibello W, Sanavio F, Severino A, Danè A, Gammaitoni L, Fagioli F, Perissinotto E, Cavalloni G, Kollet O, Lapidot T, Aglietta M

机构信息

Department of Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino, Italy.

出版信息

Blood. 1999 Jun 1;93(11):3736-49.

Abstract

Understanding the repopulating characteristics of human hematopoietic stem/progenitor cells is crucial for predicting their performance after transplant into patients receiving high-dose radiochemotherapy. We have previously reported that CD34(+) cord blood (CB) cells can be expanded in vitro for several months in serum containing culture conditions. The use of combinations of recombinant early acting growth factors and the absence of stroma was essential in determining this phenomenon. However, the effect of these manipulations on in vivo repopulating hematopoietic cells is not known. Recently, a new approach has been developed to establish an in vivo model for human primitive hematopoietic precursors by transplanting human hematopoietic cells into sublethally irradiated nonobese diabetic severe combined immunodeficient (NOD/SCID) mice. We have examined here the expansion of cells, CD34(+) and CD34(+)38(-) subpopulations, colony-forming cells (CFC), long-term culture initiating cells (LTC-IC) and the maintenance or the expansion of SCID-repopulating cells (SRC) during stroma-free suspension cultures of human CD34(+) CB cells for up to 12 weeks. Groups of sublethally irradiated NOD/SCID mice were injected with either 35,000, 20,000, and 10,000 unmanipulated CD34(+) CB cells, which were cryopreserved at the start of cultures, or the cryopreserved cells expanded from 35,000, 20,000, or 10,000 CD34(+) cells for 4, 8, and 12 weeks in the presence of a combination of early acting recombinant growth factors (flt 3/flk2 ligand [FL] + megakaryocyte growth and development factor [MGDF] +/- stem cell factor [SCF] +/- interleukin-6 [IL-6]). Mice that had been injected with >/=20,000 fresh or cryopreserved uncultured CD34(+) cells did not show any sign or showed little engraftment in a limited number of animals. Conversely, cells that had been generated by the same number of initial CD34(+) CB cells in 4 to 10 weeks of expansion cultures engrafted the vast majority of NOD/SCID mice. The level of engraftment, well above that usually observed when the same numbers of uncultured cells were injected in the same recipients (even in the presence of irradiated CD34(-) cells) suggested that primitive hematopoietic cells were maintained for up to 10 weeks of cultures. In addition, dilution experiments suggest that SRC are expanded more than 70-fold after 9 to 10 weeks of expansion. These results support and extend our previous findings that CD34(+) CB stem cells (identified as LTC-IC) could indeed be grown and expanded in vitro for an extremely long period of time. Such information may be essential to design efficient stem cell expansion procedures for clinical use.

摘要

了解人类造血干/祖细胞的重新填充特性对于预测其移植到接受高剂量放化疗患者体内后的表现至关重要。我们之前曾报道,CD34(+)脐血细胞(CB)在含血清培养条件下可在体外扩增数月。重组早期作用生长因子的组合使用以及无基质环境对于确定这一现象至关重要。然而,这些操作对体内重新填充造血细胞的影响尚不清楚。最近,通过将人类造血细胞移植到亚致死剂量照射的非肥胖糖尿病严重联合免疫缺陷(NOD/SCID)小鼠体内,开发出了一种建立人类原始造血前体细胞体内模型的新方法。我们在此研究了人类CD34(+) CB细胞在无基质悬浮培养长达12周期间细胞、CD34(+)和CD34(+)38(-)亚群、集落形成细胞(CFC)、长期培养起始细胞(LTC-IC)的扩增以及严重联合免疫缺陷(SCID)重新填充细胞(SRC)的维持或扩增情况。将亚致死剂量照射的NOD/SCID小鼠分组,分别注射35000、20000和10000个未处理的CD34(+) CB细胞(这些细胞在培养开始时冷冻保存),或者从35000、20000或10000个CD34(+)细胞在早期作用重组生长因子(Flt 3/Flk2配体[FL]+巨核细胞生长和发育因子[MGDF]+/-干细胞因子[SCF]+/-白细胞介素-6[IL-6])组合存在的情况下扩增4、8和12周后冷冻保存的细胞。注射了≥20000个新鲜或冷冻保存的未培养CD34(+)细胞的小鼠没有表现出任何迹象,或者在少数动物中仅有少量植入。相反,在4至10周的扩增培养中由相同数量的初始CD34(+) CB细胞产生的细胞植入了绝大多数NOD/SCID小鼠。植入水平远高于在相同受体中注射相同数量未培养细胞时通常观察到的水平(即使存在照射的CD3 (-)细胞),这表明原始造血细胞在长达10周的培养中得以维持。此外,稀释实验表明,在扩增9至10周后SRC扩增了70多倍。这些结果支持并扩展了我们之前的发现,即CD34(+) CB干细胞(鉴定为LTC-IC)确实可以在体外长时间生长和扩增。这些信息对于设计用于临床的有效干细胞扩增程序可能至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验